Pfizer swung to a loss and posted a sharp drop in quarterly sales, weighed down by soft demand for its Covid-related products.
The pharmaceutical giant posted a 70% drop in operational sales, adjusted for currency fluctuations, of its Covid-19 vaccine, ahead of the launch of new variant shots. Operational sales of the company’s Paxlovid treatment tumbled 97% ahead of the commercial transition of that drug.
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel
